Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Humanigen Inc

HGEN
Current price
0.005 USD 0 USD (0.00%)
Last closed 0.005 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 595 400 USD
Yield for 12 month -96.46 %
Week
Month
Year
HGEN
21.11.2021 - 28.11.2021

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. Address: 830 Morris Turnpike, Short Hills, NJ, United States, 07078-2625

Analytics

WallStreet Target Price

0.15 USD

P/E ratio

Dividend Yield

Current Year

+2 514 000 USD

Last Year

+3 595 000 USD

Current Quarter

+221 000 USD

Last Quarter

+221 000 USD

Current Year

+2 514 000 USD

Last Year

+3 595 000 USD

Current Quarter

+221 000 USD

Last Quarter

+221 000 USD

Key Figures HGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -8 979 750 USD
Operating Margin TTM -1916.29 %
PE Ratio
Return On Assets TTM -85.05 %
PEG Ratio
Return On Equity TTM -2165.43 %
Wall Street Target Price 0.15 USD
Revenue TTM 1 699 000 USD
Book Value -0.42 USD
Revenue Per Share TTM 0.017 USD
Dividend Share
Quarterly Revenue Growth YOY -78.7 %
Dividend Yield
Gross Profit TTM -209 520 000 USD
Earnings Share -0.51 USD
Diluted Eps TTM -0.51 USD
Most Recent Quarter I 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics HGEN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History HGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:5
Payout Ratio
Last Split Date 14.09.2020
Dividend Date 14.09.2020

Stock Valuation HGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 9.3897
Enterprise Value Revenue 0.0488
Price Sales TTM 0.3504
Enterprise Value EBITDA 0.4096
Price Book MRQ 9.2014

Financials HGEN

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators HGEN

For 52 weeks

0.0001 USD 0.24 USD
50 Day MA 0.0049 USD
Shares Short Prior Month 3 324 356
200 Day MA 0.088 USD
Short Ratio 1.52
Shares Short 3 598 599
Short Percent 3.88 %